Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
251
resultados
Última actualización
16/10/2026 [06:52:00]
Resultados 50 a 75 de 251
Resumen de: CN122874433A
本发明提供一种西蓝花外泌体负载二氧化铈复合材料及其制备方法，本发明以西蓝花来源的外泌体为天然纳米载体，以二氧化铈颗粒为功能活性组分，通过提取纯化、表面结合或包载复合、纯化分离等步骤，构建形成一种兼具植物来源生物相容性与持续抗氧化能力的复合材料。
Resumen de: CN122874429A
本发明公开了一种基于中性粒细胞“生‑死”杂化膜的纳米递药系统及其制备方法和应用，涉及制药技术领域。该方法是将中性粒细胞膜（Neu‑M）固有的炎症组织浸润和促炎因子吸附能力，与中性粒细胞凋亡囊泡膜（ApoV‑M）的巨噬细胞靶向能力协同整合，并共同包覆于可释放CO的功能核心之上。本发明是将新材料（细胞膜包裹纳米药物）和新技术（气体治疗）有机融合的新尝试，有望突破单一疗法的局限性，为中性粒细胞“生‑死”杂化膜和CO气体的生物医学应用提供新的见解。
Resumen de: CN122874435A
本发明涉及微生物侵染响应型金属‑多酚/肉桂醛纳米胶囊、制备方法及应用，其中，纳米胶囊的制备方法，包括如下步骤：步骤1、金属配位交联：向单宁酸‑肉桂醛乳液中滴加镓盐溶液，滴加结束后熟化处理，镓离子与单宁酸的配位自组装形成负载肉桂醛的金属‑多酚网络内核，得内核分散液；步骤2、透明质酸包覆：将步骤1所得的内核分散液加入透明质酸溶液中，使透明质酸包覆于金属‑多酚网络内核表面，然后离心、洗涤，得金属‑多酚/肉桂醛纳米胶囊。本发明能够利用细菌微环境（如酶）触发释放活性成分肉桂醛和镓离子，协同实现肉桂醛和镓离子对浮游菌及生物膜的高效清除，可用于制备食品保鲜剂、抗菌剂或抗菌药物。
Resumen de: WO2025186788A1
The present disclosure is directed to methods for characterization of a sample by size exclusion chromatography (SEC), the sample including intact lipid nanoparticles (LNPs). The method generally includes loading the sample on a chromatographic column having an SEC packing material disposed therein, flowing a mobile phase through the SEC packing material to elute the intact LNPs, and detecting the eluted intact LNPs. The mobile phase includes an organic solvent, an aqueous buffer, and a non-ionic surfactant.
Resumen de: WO2025173025A1
Biodegradable microcapsule powder formulation and preparation thereof The present invention provides a stable biodegradable microcapsule powder formulation comprising actives such as fragrance-containing biodegradable microcapsules in synergistic combination with biopolymer(s), naturally-occurring small molecules, additives, and optionally cationic polymer, and preparation thereof. Said formulation is a free-flowable microplastic-free powder that possesses good storage stability, improved loading of fragrance, and better deposition of said microcapsules on a substrate such as fabric. Said microcapsules powder exhibits improved performance of delivery of actives such as fragrances onto substrates such as fabric surface through rinse off and leave on formulations.
Resumen de: WO2025160177A1
The present disclosure provides compositions which facilitate preferential targeting or delivery of a therapeutic agent to a particular organ, cell, or tissue. The presently disclosed compositions comprise lipid nanoparticles formed from a covalent-bond forming lipid, a cationic lipid, and, in some embodiments, a steroid or sterol, a phospholipid, and a PEG lipid.
Resumen de: CN122878547A
本发明公开了一种赋予纳米颗粒肺靶向功能的聚氨基酸及其制备方法与应用，所述聚氨基酸为三嵌段聚氨基酸，由中间的亲水嵌段与两端的疏水嵌段组成，亲水嵌段为负电荷α‑螺旋构象，其刚性结构可为疏水嵌段的充分暴露提供结构支撑；一端疏水嵌段通过疏水相互作用修饰多种脂基纳米递送系统，另一端疏水嵌段暴露于递送系统表面并使其具备原位红细胞搭便车能力与肺靶向能力，可用于肺部疾病靶向治疗；本发明还比较了不同的聚氨基酸构象、亲水嵌段聚合度、疏水组分以及聚氨基酸后插入比例的效果，并通过体外与体内试验验证了所述聚氨基酸赋予纳米颗粒肺靶向功能的可行性，为实现安全、高效、普适性的肺靶向药物递送提供了全新的技术方案。
Resumen de: CN122874432A
本发明涉及一种线粒体来源仿生囊泡及其制备方法与应用。包括：从细胞中分离提取线粒体；将线粒体置于含药物的PBS溶液中，得到含有线粒体与药物的PBS溶液，使用脂质体挤出器将其通过聚碳酸酯膜，得到滤液，而后滤液使用超滤管离心，收集内管截留液，即得线粒体来源仿生囊泡。与现有技术相比，本发明制备得到的线粒体来源仿生囊泡的粒径<200nm，有利于软骨穿透和细胞摄取，且该线粒体来源仿生囊泡还保留了线粒体的同源靶向能力，能够将药物精准递送至功能受损的线粒体网络。此外，体外实验证明，本发明制备得到的线粒体来源仿生囊泡能够显著增加软骨细胞外基质核心组分COL2和ACAN的表达；使ATP生成增加，ROS降低。
Resumen de: CN122878245A
本发明提供了一种化合物、脂质纳米颗粒及其用途。所述化合物具有式(I)所示的结构，且可作为脂质体纳米颗粒药物载体，负载带有负电的药物活性成分，并将药物活性成分送呈至细胞内并有效从内涵体中逃逸至胞浆，利于所负载的药物活性成分发挥药效，且具有毒性低和稳定性高等优点。式（I）
Resumen de: US20260306584A1
0000 The present invention provides an improved process for preparing a stable lyophilized composition comprising lipid nanoparticles encapsulating mRNA, which results in high mRNA integrity suitable for both short- and long-term storage for therapeutic use. In some embodiments, the present invention provides a method of preparing a stable lyophilized composition comprising the steps of adding ascorbic acid to an aqueous solution comprising one or more lipid nanoparticles, freezing the aqueous solution to obtain a frozen solution, drying the frozen solution to obtain a lyophilized composition, and increasing and holding the temperature of the lyophilized composition to a temperature of between 15° C. to 30° C.
Resumen de: US20260307330A1
0000 Described are techniques, systems, and methods including those employing multi-channel controlled pneumatic printheads which contain a linker (e.g. Luer lock), a designed functional system (e.g., a microfluidic system, coaxial system, bi/tri-axial, or a mixing system), and one or more outlets (e.g., nozzle part or output linker). The printheads are useful for pneumatic, pressure assisted, extrusion-based 3D printing and emulsion/mixture evaporation for fabricating particles that may encapsulate an active pharmaceutical ingredient or live cells into a biocompatible polymer.
Resumen de: AU2026233984A1
The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer. cancer. ep e p c a n c e r
Resumen de: US20260306417A1
0000 The present disclosure relates to oral targeted nano delivery systems containing geniposide, and preparation methods, and application thereof, and in particular, to the field of pharmaceuticals. The methods include synthesizing MSNs with a Stöber method using a template; removing the template, modifying a surface of the MSNs with amino groups to obtain MSN@NH<2>; adding HA activated by NHS/EDCI to a suspension of the MSN@NH<2>, and reacting to obtain MSN-HA; utilizing the MSN-HA, a chitosan solution, and sodium alginate to prepare Chi/Alg@MSN-HA nanoparticles (NPs); and loading the geniposide with the Chi/Alg@MSN-HA NPs in a proportional ratio to prepare geniposide-loaded Chi/Alg-GE@MSN-HA NPs. In the present disclosure, by constructing a targeted nano delivery system and changing the site of administration, the anti-UC efficacy of the geniposide is improved and a solution is provided for the safety problem of the geniposide by realizing the localized release of the geniposide in the colon.
Resumen de: US20260306407A1
0000 A drug production facility includes: a first module comprising drug substance and drug product manufacturing equipment including equipment for producing RNA-based drug substance, lipid nanoparticle (LNP)-based drug products and lipoplex-based drug products; and a second module that includes fill and finish process equipment.
Resumen de: US20260306598A1
0000 The present disclosure relates to a process for the preparation of tolerizing immune modifying nanoparticles encapsulating antigens associated with primary biliary cholangitis (PBC), compositions comprising the particles and use thereof for the treatment of PBC.
Resumen de: US20260306510A1
This invention relates to a process of preparing an oil-in-water emulsion comprising testosterone for use in a pump-action dispensing device. It further relates to the oil-in-water emulsion produced by the process of the invention, and the combination of the emulsion with a pump-action dispensing device.
Resumen de: US20260306418A1
The purpose of the present invention is to implement a hydrophobic drug as a transdermal drug delivery system (TDDS). The present invention relates to: silica-based nanoparticles for the sustained release of a hydrophobic drug, the silica-based nanoparticles comprising hollow nanoparticles that include a hollow core layer and a silica matrix shell layer, and the hydrophobic drug loaded into the hollow nanoparticles; a method for preparing same; and a transdermal drug delivery system comprising same.
Resumen de: WO2026212425A1
The present invention relates to lipid nanoparticles conjugated with a clusterin-fused antibody, in which: (1) the antibody can be stably attached to the surface of the lipid nanoparticles using clusterin; (2) continuous target binding of the antibody can be induced by preventing substitution by serum proteins through clusterin-antibody binding; (3) an antibody-nanoparticle complex can be prepared without chemical modification by using the high lipid affinity of clusterin; (4) antibody structural modification that occurs in conventional chemical covalent conjugation methods can be prevented; (5) the efficiency of delivery to target cells and tissues can be increased through the antibody-nanoparticle complex using clusterin; and (6) various antibody-based drug delivery systems can be developed based on the present invention.
Resumen de: US20260306528A1
This disclosure concerns a hydrogel ink comprising lipid particles, polynucleotides loaded within the lipid particles and a bioink. In one embodiment, the lipid particles comprise extracellular vesicles. The disclosure also concerns the hydrogel thereof, and its use in treating a neural disease or condition, or regenerating a soft tissue.
Resumen de: US20260308526A1
The present disclosure relates to microRNAs (miRs) and extracellular vesicles comprising same and therapeutic uses thereof, for example, in modulating angiogenesis.
Resumen de: US20260306660A1
Disclosed herein are thrombin-sensitive platelet like particles. The particles can be used to promote healing in a variety of wounds and can be used in drug delivery systems.
Resumen de: US20260308268A1
0000 Aspects of the disclosure relate to compositions comprising encapsulated immunotoxins and methods for using the encapsulated immunotoxins. The encapsulated immunotoxins may be capable of reaching otherwise difficult to target tissues, such as the brain, and may resist denaturation and degradation prior to reaching the targeted tissue.
Resumen de: US20260306656A1
Disclosed herein are compositions comprising purified red blood cell membrane fragments (RBCMFs) as well as methods of making and using thereof.
Resumen de: US20260306420A1
0000 A stable polymer-lipid nanoparticle for drug binding and delivery comprising a core containing polylactic-co-glycolic acid (PLGA) and polyvinyl alcohol (PVA) and a core envelope containing a mixture of lipids: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DDPC), cholesterol and the ammonium salt of 1,2-distearoyl-sn-glycero-3-phospho-ethanolamine-N-arnino(polyethylene glycol)-2000 (DSPE-PEG(2000)NH2 and a method for producing such particles.
Nº publicación: WO2026213608A1 08/10/2026
Solicitante:
CYTODIGM INC [US]
CYTODIGM, INC.
Resumen de: WO2026213608A1
The present invention provides a targeted lipid nanoparticle (tLNP) comprising a bispecific antibody and a core lipid nanoparticle comprising a ganglioside and a therapeutic agent, for delivery to specific cell types such as immune cells and hematopoietic stem cells, wherein the bispecific antibody binds to the core lipid nanoparticle through affinity binding. The invention also provides a method for treating a disease or condition using the tLNP compositions described herein.
BOPI
Sede Electrónica
